☆ 4.7 Letter

Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells

ANNALS OF ONCOLOGY (2016)

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue 3, Pages 546-547

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdv580

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Nivolumab has shown promising early results in patients with advanced malignancies, including melanoma and lung cancer, with generally manageable side effects. On the other hand, recent studies showed that the immune activation caused by PD-1 blockade might promote severe autoimmune toxicity. Herein, we report a case of idiopathic thrombocytopenic purpura during nivolumab therapy.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma

W. J. Mullally, F. J. Cooke, I. M. Crosbie, S. Kumar, V. E. Abernethy, E. J. Jordan, M. O'Connor, A. M. Horgan, R. Landers, J. Naidoo, P. M. Calvert

Summary: This is a case of a man in his early 50s who presented with small bowel obstruction and was found to have metastatic melanoma without a primary lesion. After receiving immunotherapy, the patient developed a series of symptoms and eventually died from immune-related thrombotic thrombocytopenic purpura (TTP).

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane

Summary: Summary: This study presented the long-term follow-up results of the IDO/PD-L1 vaccine and nivolumab combination therapy in cohort A, showing promising efficacy with high overall response rates and durable responses. However, cohort B did not show significant clinical effects.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Ari VanderWalde, Shay L. Bellasea, Kari L. Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances Collichio, Jeffrey A. Sosman, Alexandra Ikeguchi, Adrienne I. Victor, Thach-Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A. Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu-Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu, Antoni Ribas

Summary: In this randomized phase 2 trial, combination therapy of ipilimumab and nivolumab showed significant improvement in progression-free survival in patients with metastatic melanoma compared to ipilimumab alone. However, the impact on CD8 T cell infiltrate in tumor was not statistically significant.

NATURE MEDICINE (2023)

Add to Collection

Article Microbiology

Detection of Helicobacter pylori from Extracted Teeth of a Patient with Idiopathic Thrombocytopenic Purpura

Masakazu Hamada, Ryota Nomura, Saaya Matayoshi, Yuko Ogaya, Hiroyasu Kameyama, Narikazu Uzawa, Kazuhiko Nakano

Summary: This study describes the presence of Helicobacter pylori in the oral cavity of a patient with immune thrombocytopenic purpura (ITP). The results suggest that teeth with severe bacterial infections may serve as potential reservoirs for H. pylori in patients with ITP.

MICROORGANISMS (2022)

Add to Collection

Article Immunology

Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells

Lena Margarethe Wulfken, Juergen Christian Becker, Rami Hayajneh, Annette Doris Wagner, Katrin Schaper-Gerhardt, Nina Flatt, Imke Grimmelmann, Ralf Gutzmer

Summary: The use of PD-1 inhibitors in a 48-year-old female patient with metastatic melanoma led to a deep partial response, despite the depletion of B cells due to prior rituximab treatment. The presence of regulatory B cells did not seem to be necessary for the efficacy of PD-1 inhibitors in this case, and their depletion may have even improved treatment outcomes.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient

George Samonis, Aikaterini Bousmpoukea, Aristea Molfeta, Antonios D. Kalkinis, Kalliopi Petraki, Christos Koutserimpas, Dimitrios Bafaloukos

Summary: Nivolumab, an anti-PD-1 check point inhibitor used in the treatment of melanoma, can cause severe toxicities. This article presents a case of delayed nivolumab-induced severe gastritis in a patient suffering from metastatic melanoma. The symptoms from the upper GI tract appeared 4 months after the initiation of nivolumab treatment.

DIAGNOSTICS (2022)

Add to Collection

Article Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Ines Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gerard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Celeste Lebbe, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne N. Lo, Christian U. Blank, Alexander M. Menzies, Georgina V. Long

Summary: The study indicates that for patients resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 appears to offer higher efficacy compared to ipilimumab monotherapy, with a higher objective response rate, prolonged progression-free survival, longer overall survival, and a similar rate of grade 3-5 toxicity.

LANCET ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

NMR-Based Metabolomics Identify Metabolic Change in Spleen of Idiopathic Thrombocytopenic Purpura Patients

Shi Wen, Zhenzhao Wang, Jianghua Feng, Yuanyuan Yang, Xianchao Lin, Heguang Huang

Summary: This study investigated the metabolomic changes in the spleen of patients with Idiopathic Thrombocytopenic Purpura (ITP) using H-1 MAS NMR. The results showed that the concentrations of several metabolites were altered in the spleen of ITP patients compared to normal spleen. The decrease in taurine level was identified as a potential diagnostic and efficacy-predictive biomarker for ITP treatment.

METABOLITES (2022)

Add to Collection

Editorial Material Oncology

PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma.. .But for How Long?

Ryan C. Augustin, Jason J. Luke

Summary: This article discusses the 5-year update of the pivotal trial CheckMate-238 and provides context to its results considering limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Ines Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pfoehler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies

Summary: This study aimed to build multivariable predictive models for response and survival outcomes in metastatic melanoma patients treated with immunotherapy. By analyzing clinical characteristics and baseline blood parameters, the final models for predicting treatment response, progression-free survival, and overall survival were developed and nomogram calculators were created.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab exposure in a hemodialysis patient with metastatic melanoma

Judith L. Gulikers, Sander Croes, Marco J. W. Schreurs, Elisabeth J. R. Litjens, Maureen J. B. Aarts, Robin M. J. M. van Geel

Summary: The study found that IHD does not significantly influence the serum concentrations of nivolumab in patients, and nivolumab treatment appears to be well tolerated without complications in patients undergoing IHD.

MELANOMA RESEARCH (2021)

Add to Collection

Article Medicine, Research & Experimental

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology

Bettina Sobottka, Marta Nowak, Anja Laura Frei, Martina Haberecker, Samuel Merki, Mitchell P. Levesque, Reinhard Dummer, Holger Moch, Viktor Hendrik Koelzer

Summary: CD8+ tumor-infiltrating T cells play a crucial role in predicting responses to immune checkpoint inhibitors in immune-oncology. A computational diagnostic algorithm was established to quantitatively measure the spatial densities of these cells in tumor compartments, leading to the successful classification into immune diagnostic categories. This approach allows for efficient immune phenotyping of metastatic lesions, even in the absence of material from the invasive margin, providing valuable insights for immunotherapy strategies in metastatic melanoma.

LABORATORY INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew Williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, Paolo A. Ascierto

Summary: This retrospective multicenter study evaluates the impact of diabetes on the efficacy of nivolumab plus the LAG3 inhibitor relatlimab in advanced melanoma patients. The study found that LAG3 inhibition has reduced efficacy in patients with type 2 diabetes, possibly due to reduced expression of LAG3 in tumor tissue. In addition, patients with increased blood glucose levels after 3 months of treatment have poorer prognosis.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Oncology

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

Meredith S. Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, Maura S. Glover, Rinata Simien, Adi Diab, Patrick Hwu, Brett W. Carter, Sapna P. Patel

Summary: The combination regimen of nivolumab plus ipilimumab shows activity in metastatic uveal melanoma, yielding deep and sustained confirmed responses.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Wolfram Samlowski, Camille Adajar

Summary: In patients with progressing melanoma after initial checkpoint inhibitor therapy, the addition of BRAF +/- MEK inhibitors to continued PD-1 antibody treatment as second line therapy showed substantial activity and manageable toxicity. This approach can induce durable complete responses in patients who have failed initial immunotherapy, suggesting further evaluation in suitable patients.

BMC CANCER (2021)

Add to Collection

Article Infectious Diseases

The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan

Takamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, Hiroshi Yotsuyanagi, Junko Sato, Intestu Kobayashi, Shin Iinuma, Takashi Nagayama, Shuichiro Shibuya, Natsuki Ogawa, Ken Iozumi, Yasuyuki Nakajima, Yukiko Kurikawa, Motoko Kobayashi, Koma Matsuo, Hideyuki Ishikawa, Tadamichi Shimizu, Kiyohiro Tsutsui, Tatsuyoshi Kawamura, Ryuhei Okuyama, Mariko Seishima, Yoichi Akita, Chikatoshi Kasugai, Katsuaki Yano, Yasuhiko Tamada, Kimihiko Mizutani, Kenji Kabashima, Nanako Yamada, Masami Ikeda

Summary: The present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) did not differ significantly between the present study and the 2013 survey. However, the prevalence of methicillin-resistant coagulase-negative staphylococci (MRCNS) was higher in the present study compared to the 2013 survey. The susceptibility profiles of MRSA and MRCNS to various antibiotics were not significantly different between the two surveys. Continuous monitoring is important for guiding the appropriate treatment of SSTIs.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2023)

Add to Collection

Letter Dermatology

Non-invasive visualization of epidermal hypertrophy of pachydermoperiostosis

Takayoshi Komatsu-Fujii, Corrine Sison de Jesus, Takashi Nomura, Kenji Kabashima

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Article Dermatology

The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry

Annelie H. Musters, Conor Broderick, David Prieto-Merino, Andrea Chiricozzi, Giovanni Damiani, Ketty Peris, Sandipan Dhar, Abhishek De, Esther Freeman, Bernd W. M. Arents, Tim Burton, Angela Leigh-Ann L. Bosma, Ching-Chi Chi, Godfrey Fletcher, Aaron M. Drucker, Kenji Kabashima, Emilie F. de Monchy, Maitreyee Panda, Dmitri Robert Wall, Christian Vestergaard, Emmanuel Mahe, Laura Bonzano, Leila Kattach, Maddalena Napolitano, Maria Fernanda Ordonez-Rubiano, Eva Haufe, Cataldo Patruno, Alan D. Irvine, Phyllis Spuls, Carsten Flohr

Summary: Limited data suggest that patients with atopic dermatitis (AD) receiving systemic immunomodulatory treatments have a lower risk of severe COVID-19 complications. Monotherapy with dupilumab is associated with lower hospitalization rates compared to other therapies. However, combination systemic treatments, particularly those including systemic corticosteroids, have the highest risk of severe COVID-19.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Letter Dermatology

Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis

Toshiaki Kogame, Satoru Yonekura, Paola Lovato, Masahiro Hirata, Riko Takimoto-ito, Tomoya Takegami, Takayoshi Komatsu-Fujii, Naotomo Kambe, Takashi Nomura, Mads A. Ropke, Kenji Kabashima

Summary: Despite the limited sample size and low frequency of skin ILCs in this study, the data suggest that ICOS+ ILCs express IL-13Ra1 and that the density of ICOS+ ILCs decreases after four weeks of tralokinumab treatment.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Increased type I interferon expression from T cells in lesional skin of Degos disease

Yuki Honda Keith, Atsushi Otsuka, Toshiaki Kogame, Hiroyuki Ito, Shunya Usui, Masakazu Fujimoto, Keita Jinnouchi, Masahiro Hirata, Kazumitsu Sugiura, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Letter Dermatology

A case of Kimura disease with atopic dermatitis successfully treated with baricitinib

Marina Ueda, Toshiaki Kogame, Gyohei Egawa, Naotomo Kambe, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis A Post Hoc Analysis of 6 Randomized Clinical Trials

Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir

Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.

JAMA DERMATOLOGY (2023)

Add to Collection

Article Allergy

Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan

Riko Takimoto-Ito, Naotomo Kambe, Toshiaki Kogame, Takashi Nomura, Kazushi Izawa, Tomoyasu Jo, Yasuhiro Kazuma, Hajime Yoshifuji, Yuya Tabuchi, Hiroyasu Abe, Mayuko Yamamoto, Kimiko Nakajima, Ozumi Tomita, Yosuke Yagi, Kazumoto Katagiri, Yuki Matsuzaka, Yohei Takeuchi, Miho Hatanaka, Takuro Kanekura, Sora Takeuchi, Takafumi Kadono, Yuya Fujita, Kiyoshi Migita, Takahiro Fujino, Takahiko Akagi, Tomoyuki Mukai, Tohru Nagano, Mitsuhiro Kawano, Hayato Kimura, Yukari Okubo, Akimichi Morita, Michihiro Hide, Takahiro Satoh, Akihiko Asahina, Nobuo Kanazawa, Kenji Kabashima

Summary: Schnitzler syndrome is a rare disorder characterized by chronic urticaria. A nationwide survey was conducted in Japan to determine the current status of the disease. Clinical information of 36 diagnosed cases was collected, providing insights into the clinical features and treatment of the syndrome. Continuous collection and long-term follow-up of clinical information are crucial for the appropriate management and further understanding of Schnitzler syndrome.

ALLERGOLOGY INTERNATIONAL (2023)

Add to Collection

Review Immunology

Mast cells in type 2 skin inflammation: Maintenance and function

Yuki Honda Keith, Gyohei Egawa, Tetsuya Honda, Kenji Kabashima

Summary: Mast cells (MCs) are immune cells that play important roles in maintaining homeostasis and inflammatory states in tissues. They are involved in the pathogenesis of type 2 skin inflammation in atopic dermatitis (AD) through both pro- and anti-inflammatory effects. The activation of skin MCs by environmental factors like Staphylococcus aureus can lead to AD inflammation, while MCs also contribute to pruritus through IgE-dependent and -independent degranulation. On the other hand, MCs can suppress type 2 skin inflammation by promoting Treg expansion and enhancing skin barrier function.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Add to Collection

Review Immunology

Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: Insights from pharmacological and genetic approaches

Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Lipid mediators act through specific receptors on cell surfaces and play physiological roles locally at their production sites. Recent research has shed light on the roles of these mediators in various diseases, including inflammatory skin conditions. They not only signal themselves, but also enhance the signaling of other chemical mediators. Manipulating their signaling has the potential to be a novel therapeutic approach for human skin diseases.

IMMUNOLOGICAL REVIEWS (2023)

Add to Collection

Article Dermatology

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima

Summary: The background data from the Japanese phase 3 study showed that nemolizumab in combination with topical treatments can reduce pruritus in atopic dermatitis. This post-hoc analysis found that improvements in pruritus were associated with improvements in eczema symptoms, sleep quality, and daily life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Letter Dermatology

A Japanese case of Vorner-type palmoplantar keratoderma caused by a novel KRT1 variant

Satoshi Nakamizo, Teruasa Murata, Yoshihiro Ishida, Satomi Aoki, Takashi Sasaki, Akiharu Kubo, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Pathology

Cutaneous arteritis with intimal fibrin ring and immature myeloid cell infiltrate: lymphocytic thrombophilic arteritis or histiocytoid polyarteritis nodosa?

Masakazu Fujimoto, Toshiya Miyake, Yo Kaku, Masahiro Hirata, Kenji Kabashima, Hironori Haga

Summary: This study aimed to resolve the ongoing debate on whether lymphocytic thrombophilic arteritis (LTA) is a separate disease or a type of polyarteritis nodosa (PAN). Immunohistochemistry analysis of skin biopsies from five LTA patients revealed that the majority of infiltrating cells were myelomonocytic cells rather than lymphocytes. Based on these findings, PAN was considered a more appropriate diagnosis for the five cases. Further investigation is needed to determine if histiocytoid PAN with immature myeloid cells is the same disease as conventional PAN with mature neutrophils.

VIRCHOWS ARCHIV (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Mead acid inhibits retinol-induced irritant contact dermatitis via peroxisome proliferator-activated receptor alpha

Azusa Saika, Prabha Tiwari, Takahiro Nagatake, Eri Node, Koji Hosomi, Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Mead acid can suppress retinol-induced irritant contact dermatitis and prevent keratinocyte hyperproliferation and the expression of neutrophil chemoattractants through the PPAR-alpha pathway.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Add to Collection

Letter Dermatology

Lymphedema-associated angiosarcoma uniquely localized on the left thigh and anterior abdominal wall secondary to central obesity and multiple surgeries

Yui Hirano-Lotman, Toshiaki Kogame, Yo Kaku, Takayoshi Komatsu-Fujii, Yuichiro Endo, Takashi Nomura, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.